Logo Image
News|Articles|August 15, 2023

FDA Accepts NDA for Venatorx Pharmaceuticals’ Cefepime-Taniborbactam for Complicated UTIs

The Prescription Drug User Fee Act (PDUFA) action date is scheduled for the first quarter of 2024.

The FDA has accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic for the potential treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis.

“The NDA acceptance represents the culmination of unwavering dedication, scientific excellence, and the collaborative efforts of our talented team, partners, and clinical investigators,” Venatorx CEO Christopher J. Burns, PhD, said in a statement. “Cefepime-taniborbactam exemplifies our commitment to innovation and improving patient outcomes. By addressing the evolving and increasing challenges posed by antimicrobial resistance, we aim to make a meaningful impact on global public health.”

The PDUFA target action date is set for February 22, 2024.

In previous reporting by Contagion, the company offered insights on its phase 3 CERTAIN-1 study, which demonstrated cefepime-taniborbactam was superior to meropenem for the primary efficacy endpoint of composite microbiologic and clinical success at the Test of Cure (TOC) visit (Day 19-23) in the microbiological intent-to-treat (microITT) population.

At end of treatment (Day 7-14), response rates were 89.1% for cefepime-taniborbactam and 86% for meropenem, and at Day 28-35 they were 63.8% and 51.7% respectively.

The study included 661 hospitalized patients with complicated urinary tract infections, including acute pyelonephritis, receiving either 2.5 g of cefepime-taniborbactam or 1 g of meropenem every eight hours. The average age of study participants was 56.2 and 52.8% were female.

Cefepime-taniborbactam was well-tolerated and no new safety findings were identified. Treatment-emergent adverse events occurred in 35.5% of patients in the cefepime-taniborbactam group and 29% of patients in the meropenem group, including headache, diarrhea, constipation, hypertension, and nausea.

“Due to its broad spectrum of in-vitro activity against established and rapidly increasing mechanisms of carbapenem resistance such as serine- and metallo-beta-lactamases and the positive results demonstrated in CERTAIN-1, cefepime-taniborbactam, if approved, will address a critical unmet need and be a potentially essential treatment option in the continuing fight against antimicrobial resistance in gram-negative bacterial infections,” Venatorx Senior Vice President, Medical Sciences, Paul McGovern, MD, said in a statement.

Watch this Contagion interview with Burns back in 2021 about innovation in antibiotic development as well as more information on cefepime-taniborbactam.

Related to this article

View more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Drawing Borders Around a Borderless Specialty
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Read more
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
Read more
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.
Read more